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The immunomodulador glatiramer acetate (GA) has been shown to significantly reduce the severity of symptoms during the course of
multiple sclerosis and in its animal model - experimental autoimmune encephalomyelitis (EAE). Since GA may influence the response of
non-neuronal cells in the spinal cord, it is possible that, to some extent, this drug affects the synaptic changes induced during the
exacerbation of EAE. In the present study, we investigated whether GA has a positive influence on the loss of inputs to the motoneurons
during the course of EAE in rats. Lewis rats were subjected to EAE associated with GA or placebo treatment. The animals were sacrificed
after 15 days of treatment and the spinal cords processed for immunohistochemical analysis and transmission electron microscopy. A
correlation between the synaptic changes and glial activation was obtained by performing labeling of synaptophysin and glial fibrillary
acidic protein using immunohistochemical analysis. Ultrastructural analysis of the terminals apposed to alpha motoneurons was also
performed by electron transmission microscopy. Interestingly, although the GA treatment preserved synaptophysin labeling, it did not
significantly reduce the glial reaction, indicating that inflammatory activity was still present. Also, ultrastructural analysis showed that GA
treatment significantly prevented retraction of both F and S type terminals compared to placebo. The present results indicate that the
immunomodulator GA has an influence on the stability of nerve terminals in the spinal cord, which in turn may contribute to its
neuroprotective effects during the course of multiple sclerosis.
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Introduction
Multiple sclerosis (MS) is a central nervous system
demyelinating and degenerative disease of unknown etiol-
ogy, although, once initiated, it actively involves the immune
system. Demyelination similar to that seen during the course
of MS may be induced in animals, in a model called
experimental autoimmune encephalomyelitis (EAE) (1-5).
During the course of EAE, damage to the axons as well as
the occurrence of synaptic plasticity phenomena in the
brain and spinal cord contribute to the clinical signs of the
disease (3,6,7). Synaptic plasticity in the spinal cord may
explain, at least in part, the rapid sensorimotor recovery of
the animals soon after tetraplegia (3,5).
180
Braz J Med Biol Res 42(2) 2009
K.B. Marques et al.
www.bjournal.com.br
In view of the importance of a better understanding of
MS as well as its experimental models, major advances
in understanding how cellular and humoral immune re-
sponses contribute to the pathogenesis of these diseases
have been made in recent years (8-12). Thus, targeting
key elements of the immunological cascade that culmi-
nate in neural and glial tissue damage may offer a num-
ber of advantages over currently available treatment strat-
egies (13-17).
Glatiramer acetate (GA), an approved drug for the
treatment of MS, displays a variety of immunomodulatory
effects, decreasing the intensity and frequency of the epi-
sodes (18,19). Although its mechanism of action is not
completely known, its inhibition of central nervous system
myelin antigens by competing as an MHC ligand may be
of importance (20-22). The ability to stimulate prolifera-
tion of Th2 over Th1 cells, suppressing T-cell activity is
also of relevance as well (23). Since GA may influence the
response of non-neuronal cells in the spinal cord, this
drug may affect, to some extent, the synaptic changes
induced during the exacerbation of EAE. This hypothesis
has been explored in just a few studies dealing with optic
nerve injury or glutamate toxicity and in motoneuron dis-
ease models (24-26).
Nevertheless, the impact of GA on nervous tissue,
especially on neurons during the course of the disease, is
virtually unknown. The fact that GA influences cell prolif-
eration as well as neurotrophic factor synthesis (27) indi-
cates that the drug may have a role in synaptic elimina-
tion/retraction, changing and reducing the seriousness of
the course of the disease.
Taking into account the possible influence of GA on
plastic events in the spinal cord during the course of EAE,
the present study investigated the synaptic elimination
process as well as the astroglial reaction in the spinal
cord during the different stages of the disease, using
treatment on a daily basis with the drug.
Material and Methods
Animals
Forty adult female Lewis rats, 7 weeks old (~250 g
body weight), were obtained from the Multidisciplinary
Center for Biological Investigation (CEMIB/UNICAMP) and
housed on a 12-h light/dark cycle with free access to food
and water. The Institutional Committee for Ethics in Ani-
mal Experimentation (CEEA/IB/UNICAMP, Proc. #794-2)
approved the study, and the experiments were performed
in accordance with the guidelines of the Brazilian College
for Animal Experimentation (COBEA - http://www.cobea.
org.br/index.php?pg=Principios%20Eticos).
Induction of EAE
The rats were immunized with a single injection of
100 μL guinea pig myelin basic protein (25 μg, Sigma,
USA) associated with heat-inactivated Mycobacterium
tuberculosis H37RA (2.0 mg/mL; Difco Laboratories, USA)
and complete Freund’s adjuvant emulsion. This solution
was injected subcutaneously into the footpad of a hind
leg. A daily analysis and scoring of the signs and symp-
toms of EAE severity was carried out as follows: grade 0,
no clinical signs; grade 1, tail weakness or paralysis;
grade 2, hind leg paraparesis; grade 3, hind leg paralysis;
grade 4, complete paralysis (tetraplegia). In rats, EAE
develops as an acute monophasic disease, so that after
the peak (or exacerbation) it regresses spontaneously
within 5 days. The entire course of the disease from
immunization to the initial recovery from paralysis (ab-
sence of clinical signs) takes about 14 days. In the pres-
ent study, the analyses were performed when the EAE-
placebo group reached the peak of the disease. At that
point, all animals of the three experimental groups were
sacrificed. However, in order to have a complete course
of the disease with and without the treatment with GA, two
extra groups of EAE-placebo and EAE-GA were followed
up to the 30th day after immunization (Figure 3I and J).
Glatiramer acetate treatment
GA (batch 334218; Teva Pharmaceutical Industries,
Israel) was used throughout the study. GA treatment was
performed daily by subcutaneous injection of Copaxone
(0.5 mg·animal-1·day-1) in sodium phosphate buffer (100
μL), pH 7.4, for 2 weeks. GA treatment (N = 10) was
started 30 min after the procedures for EAE induction,
being repeated daily by subcutaneous injections for two
weeks. The controls were similarly treated with placebo
(buffered saline, 100 μL).
Specimen preparation
Two weeks after the induction of EAE, the animals were
anesthetized with a mixture of 10 mg/kg kensol (xylazine,
Köning, Argentina) and 50 mg/kg vetaset (Cetamine, USA)
and the vascular system was rinsed by transcardial perfu-
sion with sodium phosphate buffer, pH 7.4. For the immu-
nohistochemical detection of synaptophysin and glial fibril-
lary acidic protein (GFAP), the rats were fixed by vascular
perfusion with 4% paraformaldehyde in sodium phosphate
buffer, pH 7.4. Thereafter, the lumbar intumescence was
dissected out, postfixed overnight and then frozen. For
electron microscopy, 100 mL of a fixative containing 2.5%
glutaraldehyde and 0.5% paraformaldehyde in sodium
phosphate buffer, pH 7.4, were perfused through the as-
cending aorta as previously described (5). The lumbar
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spinal cord was removed and stored overnight in the same
fixative at 4°C. The specimens were then trimmed, post-
fixed with osmium tetroxide, dehydrated and embedded in
Durcupan (Fluka, Switzerland). Ultra-thin sections from the
L4-L6 segments were collected on formvar-coated copper
grids, contrasted with uranyl acetate and lead citrate, and
examined under a Leo906 transmission electron micro-
scope operated at 60 KV.
Immunohistochemistry
Transverse sections of the spinal cord (12 μm-thick)
were incubated overnight in a moist chamber at 4°C with
the following primary antibodies: human anti-synaptophysin
(Dako, Denmark, 1:100 in 3% BSA and 0.2% Triton-X in 10
mM sodium phosphate buffer, pH 7.4) was used to investi-
gate the synaptic covering, since it is a synaptic glycoprotein
found in the vesicle membrane of pre-synaptic terminals.
Goat anti-GFAP (Santa Cruz, USA, 1:200 in 3% BSA and
0.2% Triton-X in 10 mM sodium phosphate buffer, pH 7.4)
was used to analyze astrocyte reactivity. GFAP is an inter-
mediate filament that is up-regulated during astrogliosis.
After rinsing, the secondary antibodies were applied and
incubated for 45 min, according to the primary antibody
hosts (CY-2 and CY-3, Jackson ImmunoResearch, USA;
1:250). The sections were then rinsed in sodium phos-
phate buffer, pH 7.4, mounted in a mixture of glycerol/
phosphate buffer (3:1) and observed with a laser scanning
confocal microscope (Bio-Rad, USA), mounted on an
Axiovert 135 inverted microscope (Zeiss, Germany). The
excitation wavelength was 488 nm for CY-2 fluorescence
and 568 nm for CY-3 fluorescence. For quantitative meas-
urements (synaptophysin and GFAP immunoreactivity),
three representative images of the ventral horn were cap-
tured at a final magnification of 400X, with the microscope
settings being kept the same for all slides. A total of 15
sampled images from each specimen per group were
acquired and the quantification was performed with the
enhanced contrast and density slicing feature of the IMAGEJ
software (version 1.33u, National Institutes of Health, USA).
The integrated density of pixels was systematically meas-
ured in six representative areas of the lateral motor nucleus
from each section, as previously described (28). The mean
and standard error were calculated for each group and
statistical analysis was performed.
Analysis of inflammation and demyelination during the
course of EAE
The Sudan black technique was used to demonstrate
the demyelination process during disease development.
For this purpose, frozen sections were kept at room tem-
perature, rinsed with 10 mM sodium phosphate buffer,
pH 7.4, and stained with Sudan black in 70% ethanol for
30 min. The specimens were differentiated in 50% etha-
nol, rinsed with distilled water and mounted in a mixture
of glycerol/phosphate buffer (3:1).
The influx of lymphocytes close to the spinal motoneu-
rons was studied on semi-thin Toluidine blue-stained
sections obtained prior to the ultra-thin sections.
Analysis of the ultra-thin sections
Neurons with large cell bodies (average of 35 mm in
diameter) found in the sciatic motoneuron pool and cut
along the nuclear plane were identified as alpha motoneu-
rons based on the presence of C-type nerve terminals. The
surface of the cells was then sequentially digitalized at a
magnification of 10,000 using a video camera connected
to a computerized system and the acquisition feature of the
Kontron KS300 software (Zeiss). The images were then
mounted together using a vectorial software. Synaptic ter-
minals apposing the motoneuron somata were identified
and their numbers per 100 mm of cell membrane and the
membrane covering of all terminals in percent of mem-
brane length were calculated using the measurement tool
of the Image Tool software (Version 3.0, The University of
Texas Health Center in Santo Antonio, USA). The terminals
were classified as type F (with flattened synaptic vesicles,
inhibitory synapses containing glycine and GABA), type S
(with spherical synaptic vesicles, excitatory synapses con-
taining glutamate) and type C (with a subsynaptic cistern,
cholinergic synapse), according to the nomenclature by
Conradi and Skoglund (29). The distance between con-
secutive nerve terminals covering the motoneurons was
also determined. A total of 40 sciatic motoneurons (2 neu-
rons/animal in four groups of 5 animals: normal; EAE-
induced, grade 3/exacerbation; EAE-induced and GA-
treated; EAE-induced and placebo-treated) were studied.
Only large neurons present in the sciatic motor pool and
presenting at least one C-terminal were selected for the
ultrastructural analysis.
Statistical analysis
Data were analyzed by ANOVA and the results were
compared among groups by the two-tailed Student t-test
for parametric data or by the two-tailed Mann-Whitney U-
test for non-parametric data at P < 0.05 and P < 0.01. All
data are reported as mean ± SEM.
Results
Preserved synaptophysin immunolabeling and decreased
glial reaction after GA treatment
Figure 1 shows synaptophysin and GFAP immuno-
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Figure 1. Photomicrographs obtained at the level
of the spinal cord ventral horn (L4-L5) showing the
preservation of synaptophysin and an increase in
GFAP and F4/80 during the EAE peak, followed by
glatiramer acetate treatment. Panels A-D, Immuno-
labelling against synaptophysin in the normal (A),
EAE-GA (B), EAE-placebo (C), and EAE-grade 3
(D) animals. Observe the preservation of inputs in
the EAE-GA-treated group (dashed circle in B).
Panels E-H, Immunofluorescence micrographs
showing astrocyte reactivity in the normal (E), EAE-
GA (F), EAE-placebo (G), and EAE-grade 3 (H)
animals. Note that a certain degree of astrogliosis is
still present in the EAE-GA group, although the
clinical signs of the disease have been ameliorated
(dashed circle in F). Scale bar = 35 μm for all
panels. GFAP = glial fibrillary acidic protein; EAE =
experimental autoimmune encephalomyelitis; GA =
glatiramer acetate; grade 3 = hind leg paralysis.
staining. Quantitative measurements were made in the
spinal cord motor nuclei of all experimental groups and
are presented in Figure 2. The basal immunolabeling
was obtained from normal specimens showing relatively
intense synaptophysin staining (11.54 ± 0.98; mean inte-
grated density of pixels ± SEM) and rather low GFAP
levels (1.87 ± 0.18). The exacerbation of EAE (grade 3 of
the disease - paraplegia) led to a significant decrease in
synaptophysin expression in both untreated (2.77 ± 0.10,
P < 0.01) and placebo-treated animals (2.08 ± 0.29, P <
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Figure 3. Photomicro-
graphs obtained at the level
of the spinal cord ventral
horn (L4-L5) showing the
correlation between demy-
elination/inflammation and
the clinical scores for EAE.
Panels A-D, Sudan black
staining at the level of the
ventral horn of the spinal
cord showing the degree of
myelination in normal (A),
EAE-GA (peak of the dis-
ease after treatment, B),
EAE-placebo (C) and EAE-
grade 3 (D) animals. Note
that GA preserved a signifi-
cant degree of myelination




(dashed circles in C and D,
respectively). Panels E-H,
Toluidine blue-stained semi-
thin sections obtained from
the different experimental
situations. Normal (E), EAE-
GA (F), EAE-placebo (G),
and EAE-grade 3 (H). Ob-
serve the influx of immune cells in the vicinity of the motoneurons (dashed circles in G and H). Scale bar A-D = 35 μm, E-H = 15 μm. The
graphs in I and J represent schematic illustrations of the time course of the experimental autoimmune encephalomyelitis and the
correlation between the clinical scores after GA and placebo treatment. The peak of the disease occurred at about 14 days after
immunization. EAE = experimental autoimmune encephalomyelitis; GA = glatiramer acetate; grade 3 = hind leg paralysis.
Figure 2. Quantitative evaluation of the immunoreactivity under
the different experimental conditions, demonstrating the mainte-
nance of synaptic activity after GA treatment. GA treatment
significantly decreased the astroglial response in the lumbar spi-
nal cord, when compared to control groups. EAE = experimental
autoimmune encephalomyelitis; GA = glatiramer acetate; grade 3
= hind leg paralysis. *P < 0.05 (Student t-test).
0.01). Nevertheless, the GA treatment resulted in a marked
preservation of synaptophysin staining (6.44 ± 0.45, P <
0.01), especially in the motoneuron surroundings, indi-
cating a decreased loss of inputs, this observation being
coupled with the fact that GA-treated animals displayed a
milder form of the disease (Figure 3, graph I).
The decrease in input elimination after GA treatment
occurred in parallel to a significant reduction in astroglial
reaction. In this respect, GA treatment reduced GFAP
labeling (6.17 ± 0.22) to lower levels than placebo (GFAP:
10.01 ± 0.80, P < 0.01) and untreated EAE-induced speci-
mens (GFAP: 8.24 ± 0.61, P < 0.05). However, the pla-
cebo treatment resulted in a statistically significant in-
crease in GFAP labeling compared to untreated EAE-
induced rats (P < 0.05). The basal level of GFAP (1.87 ±
0.18) was significantly lower than the levels of the experi-
mental groups (P < 0.01).
Treatment with GA results in a milder form of EAE
The degree of white matter myelination in the spinal
cord was determined in Sudan black-stained sections of
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lumbar spinal cord from normal, placebo and GA-treated
animals obtained during the stage of exacerbation of the
disease (Figure 3). The degree of myelination was minimal
in placebo-treated animals in the paraplegia stage. GA-
treated rats presented lower scores and milder clinical
signs of the disease and did not reach paraplegia. Also,
axonal myelination, although reduced in comparison to
normal material, was more preserved than in the placebo
group. Representative pictures of normal, EAE-placebo,
EAE-GA, and EAE-grade 3 material are shown in Figure 3.
GA treatment preserves the synaptic terminals during
the course of EAE
Several synaptic changes were identified at the ultra-
structural level during the course of the disease in positive
control rats. Chromatolysis, cell nucleus displacement
and retraction of synapses from the cell body were ob-
served in alpha motoneurons of the spinal cord. GA treat-
ment reduced these signs, and a larger number of termi-
nals in apposition to the motoneuron cell surface were
observed. Representative examples showing the mor-
Figure 4. Transmission electron mi-
croscope micrographs obtained at the
level of the spinal cord ventral horn
(L4-L5) showing the surface of a mo-
toneuron, where the nerve terminals
are in apposition to the plasma mem-
brane (panels A-C). Panel A repre-
sents the normal covering of a control
rat. Panel B is an example of an EAE-
GA specimen - note the normal appo-
sition of the nerve terminal. Panel C,
Micrograph of a motoneuron in the
placebo-treated situation, showing an
almost fully retracted terminal. The
colorized images highlight the pre-syn-
aptic terminal in green and the moto-
neuron cytoplasm and cytoplasmic
membrane in gold. Scale bar = 0.5
μm. Panels D-G, Detailed analysis of
the synaptic covering and of the num-
ber of synaptic boutons after GA treat-
ment, revealing the positive effects of
GA compared to the placebo group.
Panel D, Graph showing the preser-
vation of both F (flattened vesicles,
inhibitory inputs) - and S (spherical
vesicles, excitatory inputs) - boutons
after GA treatment. Panels E and F,
Preservation of both inhibitory and ex-
citatory terminals by GA treatment in
both normalized (number of boutons/
100 μm of membrane) and non-nor-
malized numbers. Panel G, The but-
ton length of the F-, S- and C- (cholin-
ergic) terminals under the different ex-
perimental circumstances. EAE = ex-
perimental autoimmune encephalomy-
elitis; GA = glatiramer acetate; grade 3
= hind leg paralysis. *P < 0.05 (Stu-
dent t-test).
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phology of motoneurons and presynaptic terminals at the
dorsal lamina IX can be seen in Figure 4A-C.
In addition to qualitative observations, a detailed anal-
ysis of the afferents of these neurons was carried out and
the synaptic covering as well as the number and type of
boutons were studied. The total covering of the F, S, and C
terminals is presented in Figure 4D. A statistically signifi-
cant preservation of inputs was observed after GA treat-
ment, parallel to a reduction in the maximum score
reached after immunization. It is important to emphasize,
however, that after treatment the covering remained lower
than in the normal situation. A relevant finding is the
positive effect of the treatment for both excitatory and
inhibitory terminals (Figure 4D-G). In this respect, GA
administration preserved the mean length of apposition
as well as the number of excitatory and inhibitory inputs
(Figure 4E-G).
Pattern of button elimination induced by EAE
inflammation
To investigate whether there was a quantitative change
in the pattern of synaptic elimination, an analysis of the
frequency distribution of terminals apposed to the moto-
neuron membrane was carried out. A particular feature of
the synaptic elimination process is that the retraction of
boutons does not occur not by chance, but rather is a
finely organized event. In this respect, synaptic removal
after lesion tends to preserve clusters of terminals at
specific points along the cell membrane of injured neu-
rons. This feature is demonstrated by the fact that, in a
normal situation, a number of boutons can be found
close together. After injury, however, the distance be-
tween groups of terminals tends to increase, an event that
can be studied by observing the frequency distribution of
the gaps between boutons. Thus, during exacerbation of
the disease, the placebo-treated animals displayed an
increase in larger intervals, greater than 4 μm, exposing,
on average, an additional 35% of the motoneuron mem-
brane. Interestingly, the GA treatment that preserved more
terminals in apposition to the motoneurons resulted in a
distribution of gaps strikingly similar to that of normal
animals (Figure 5).
Figure 5. Transmission electron microscope micrographs obtained at the level of the spinal cord ventral horn (L4-L5) showing that the
distribution of the gap length between clusters of terminals apposing the cell soma membrane was close to normality after GA treatment.
Panel A, Normal distribution of intervals between nerve terminals showing that the boutons were organized in clusters of inputs. Panel
B, The distribution of terminals during the exacerbation of the disease (grade 3 = hind leg paralysis). Panel C, Treatment with GA keeps
the clusters of terminals stable regardless of the increased surrounding glial reaction. Panel D, EAE-placebo, which was similar to the
positive control (grade 3 of the disease). EAE = experimental autoimmune encephalomyelitis; GA = glatiramer acetate; F = flattened
vesicles, inhibitory inputs; S = spherical vesicles, excitatory inputs; C = cholinergic terminals.
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Discussion
The present study supports the view that maintenance
of inputs of spinal motoneurons may positively influence
their functionality during the course of EAE. This hypo-
thesis is based on the observation that, during the course
of the disease, a series of plastic phenomena involving
alpha motoneuron afferents correlate with a worsening of
the symptoms of the disease (5). Also, a highly plastic
response of the motor system after neuroinflammatory
lesion was reported by Kerschensteiner et al. (3), with
axonal remodeling being observed at multiple levels,
including the area surrounding the lesion, and above as
well as inside the motor cortex (3).
At present, the treatment of the remittent/recurrent
form of multiple sclerosis is based on the administration
of glatiramer acetate and beta interferon (4,30,31). Al-
though both are approved drugs for MS treatment, GA
has the unique characteristic of being a synthetic polymer
composed of L-alanine, L-glutamine, L-lysine and L-ty-
rosine, exerting a marked suppressive and protective
effect on EAE in various animal species (30). Interest-
ingly, although GA is not encephalitogenic, its therapeutic
effect is related to the induction of both cellular and hu-
moral immune responses in experimental models and in
humans. Currently, its therapeutic effects are attributed to
the induction of specific Th2 suppressor cells that, upon
an encephalitogenic stimulus, are able to release anti-
inflammatory cytokines that minimize the progression of
the disease (30). However, apart from such an immuno-
logical role, it is possible that GA acts directly on nervous
tissue, stimulating the release of trophic and neurotrophic
factors by the glial cells, influencing the response to the
inflammatory injuries caused by the autoimmune re-
sponse. In this respect, it has been reported that GA
induced an elevation of brain-derived neurotrophic factor,
TGF-ß, IL-4 and -10 and suppressing TNF-α and INF-γ
(10,18,32).
The effects of GA considered above may directly influ-
ence the synaptic stability of the spinal cord circuits, which
are perturbed during exacerbation of the disease. Analy-
sis of the results obtained by immunohistochemistry in
the present study showed that GA treatment significantly
preserved synaptophysin labeling in the spinal cord dur-
ing the period in which the placebo-treated animals pre-
sented a great reduction in such immunolabeling. This
observation, coupled with the decrease in clinical scores
in GA-treated animals, indicates a correlation between
synaptic activity and the degree of severity of the disease.
Interestingly, treatment with GA reduced the glial reac-
tion in the surroundings of the alpha motoneurons, as
seen by GFAP immunolabeling, as well as at the ultra-
structural level. However, the reaction was still more el-
evated than in the normal situation. This fact strengthens
the idea that a certain degree of inflammation was still
present in the motor area microenvironment. Another
aspect to be considered is that GFAP labeling was greater
in placebo-treated animals in comparison to untreated
EAE-induced rats. This may indicate that the treatment
itself, which consisted of daily subcutaneous injections,
may have caused additional stress that influenced the
immune response after immunization.
A relevant observation was obtained with Sudan black
staining, which revealed the presence of demyelination
in GA-treated animals. This indicates that the disease
was still progressing, although in a milder way than in the
placebo-treated animals. In this respect, it is acceptable
to conclude that part of the beneficial effects of treatment
is a result of the stabilization of the inputs in the spinal
cord microenvironment secondary to the control of the
autoimmune response.
The conclusions discussed above were also rein-
forced by the ultrastructural analysis of the afferents in
contact with the alpha motoneurons during the course of
the disease. These data indicated that GA treatment de-
creased the retraction of both excitatory and inhibitory
synapses to a level close to normality. Thus, the total
synaptic covering seems to have been preserved, apart
from the relatively high reactive gliosis, indicating an influ-
ence of GA on the synaptic elimination process. The
administration of GA also positively influenced the clus-
tering pattern of the terminals, which was preserved, in
contrast to the placebo-treated condition (33). Taking into
account that a motoneuron receives up to 100,000 inputs
from various sources, the maintenance of active syn-
apses is of crucial importance to the correct functionality
of the motor pathway.
The present results indicate that the immunomodula-
tor GA influences the plasticity of neural elements in the
spinal cord. This may be of relevance in the development
of new strategies for the treatment of MS based on the
use or combination of drugs capable of acting directly on
the synapses, increasing the stability of the neural cir-
cuits, which, in turn, may significantly reduce the clinical
signs of neurodegenerative diseases.
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